Life Sciences Greenhouse of Central Pennsylvania

A Venture Capital Investment Company for Life Sciences Enterprises in Central Pennsylvania

  • About Us
    • About LSGPA
    • Our Team
    • Board of Directors
  • The Funding Process
  • Resources
    • The Ecosystem
    • Applicant Support
    • Why Central PA?
  • Portfolio Companies
    • Portfolio Overview
    • Devices and Diagnostics
    • Drug Discovery
    • Other
  • News and Events
    • Press Releasees
    • Video Gallery
  • Apply Now
  • Contact Us

Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia

September 10, 2019 By Admin

BETHLEHEM, Pa.–(BUSINESS WIRE)–Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.

The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.

“Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients,” said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. “We are changing psychiatry with a single drop of blood.”

ABOUT PSYCHOSIS

Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.

ABOUT THE MyCARE INSITE CLOZAPINE TEST

The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.

ABOUT SALADAX

Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.

Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.

For more information, visit Saladax.com or MyCareTests.com.

Filed Under: News and Events

Latest News

Saladax Biomedical Expanding Access to Antipsychotic Drug Testing With Beckman Coulter Partnership

Apr 11, 2022 | Kelsy Ketchum NEW YORK – Measuring the presence of antipsychotic drugs in a patient's system is currently a time-consuming and … Read More...

THE LIFE SCIENCES GREENHOUSE OF CENTRAL PA ANNOUNCES CHANGE IN LEADERSHIP

President and CEO Mel Billingsley, PhD, Retiring after 20 Years at Helm Harrisburg, PA  ̶  March 24, 2022.  The Life Sciences … Read More...

Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada

BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics … Read More...

Immunomic Therapeutics Announces Collaboration With iOncologi

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company focused on advancing its … Read More...

Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members

ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of … Read More...

Archives

  • April 2022
  • December 2021
  • August 2021
  • July 2021
  • April 2021
  • March 2021
  • January 2021
  • November 2020
  • July 2020
  • April 2020
  • January 2020
  • September 2019
  • August 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • March 2017
  • January 2017
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • January 2016

LSGPA
Life Sciences Greenhouse of Central Pennsylvania
225 Market Street
Suite 500
Harrisburg, PA  17101
1-717-635-2100

Strawberries
LSGPA Copyright © 2018

Copyright © 2022 · WordPress · Log in